Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus
The 2014–2016 Ebola virus epidemic in West Africa triggered extensive investments from public and private partners in an attempt to slow the spread of disease and bring the outbreak under control. This significantly accelerated the pace of development of countermeasures against Zaire ebolavirus that...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1741313 |
| _version_ | 1797677301040676864 |
|---|---|
| author | Daniel N. Wolfe Marva J. Taylor Amanda G. Zarrabian |
| author_facet | Daniel N. Wolfe Marva J. Taylor Amanda G. Zarrabian |
| author_sort | Daniel N. Wolfe |
| collection | DOAJ |
| description | The 2014–2016 Ebola virus epidemic in West Africa triggered extensive investments from public and private partners in an attempt to slow the spread of disease and bring the outbreak under control. This significantly accelerated the pace of development of countermeasures against Zaire ebolavirus that enabled vaccines to be a part of an effective response to the most recent 2018–2019 outbreak in the Democratic Republic of the Congo. However, there remain urgent and unmet needs for medical countermeasures against other members of the Filoviridae family that cause viral hemorrhagic fevers. To improve the national and global preparedness posture for viral hemorrhagic fevers, a renewed emphasis is being placed on developing vaccines for filoviruses other than Zaire ebolavirus. Here we discuss lessons learned from the West Africa epidemic and how those lessons apply to the development of vaccine candidates for other filoviruses, specifically Sudan ebolavirus and Marburg virus. This commentary will highlight some of the key product development gaps to address in preparation for future disease outbreaks caused by these viruses. |
| first_indexed | 2024-03-11T22:43:13Z |
| format | Article |
| id | doaj.art-c07267d67502480d95d5826f74f89cf0 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:43:13Z |
| publishDate | 2020-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-c07267d67502480d95d5826f74f89cf02023-09-22T08:51:48ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-11-0116112855286010.1080/21645515.2020.17413131741313Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virusDaniel N. Wolfe0Marva J. Taylor1Amanda G. Zarrabian2Biomedical Advanced Research and Development AuthorityBiomedical Advanced Research and Development AuthorityBiomedical Advanced Research and Development AuthorityThe 2014–2016 Ebola virus epidemic in West Africa triggered extensive investments from public and private partners in an attempt to slow the spread of disease and bring the outbreak under control. This significantly accelerated the pace of development of countermeasures against Zaire ebolavirus that enabled vaccines to be a part of an effective response to the most recent 2018–2019 outbreak in the Democratic Republic of the Congo. However, there remain urgent and unmet needs for medical countermeasures against other members of the Filoviridae family that cause viral hemorrhagic fevers. To improve the national and global preparedness posture for viral hemorrhagic fevers, a renewed emphasis is being placed on developing vaccines for filoviruses other than Zaire ebolavirus. Here we discuss lessons learned from the West Africa epidemic and how those lessons apply to the development of vaccine candidates for other filoviruses, specifically Sudan ebolavirus and Marburg virus. This commentary will highlight some of the key product development gaps to address in preparation for future disease outbreaks caused by these viruses.http://dx.doi.org/10.1080/21645515.2020.1741313filovirusebolasudan ebolavirusmarburgvaccinemedical countermeasures |
| spellingShingle | Daniel N. Wolfe Marva J. Taylor Amanda G. Zarrabian Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus Human Vaccines & Immunotherapeutics filovirus ebola sudan ebolavirus marburg vaccine medical countermeasures |
| title | Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus |
| title_full | Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus |
| title_fullStr | Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus |
| title_full_unstemmed | Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus |
| title_short | Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus |
| title_sort | lessons learned from zaire ebolavirus to help address urgent needs for vaccines against sudan ebolavirus and marburg virus |
| topic | filovirus ebola sudan ebolavirus marburg vaccine medical countermeasures |
| url | http://dx.doi.org/10.1080/21645515.2020.1741313 |
| work_keys_str_mv | AT danielnwolfe lessonslearnedfromzaireebolavirustohelpaddressurgentneedsforvaccinesagainstsudanebolavirusandmarburgvirus AT marvajtaylor lessonslearnedfromzaireebolavirustohelpaddressurgentneedsforvaccinesagainstsudanebolavirusandmarburgvirus AT amandagzarrabian lessonslearnedfromzaireebolavirustohelpaddressurgentneedsforvaccinesagainstsudanebolavirusandmarburgvirus |